A trial of trimebutine in spastic colon.
In a double-blind crossover trial of three days duration on each drug, trimebutine in a dose of 200 mg three times daily was significantly more effective than placebo in relieving the symptoms of mild to moderate degrees of spastic colon (p less than 0.001). The only side-effect necessitating discontinuation of treatment was one case of vomiting.
D000328:Adult; D000368:Aged; D001565:Benzoates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014287:Trimebutine / Q000627:therapeutic use*
D001565:Benzoates; D014287:Trimebutine